Video

Urology Times 50 Innovations Series: Sacral neuromodulation

Author(s):

Urology Times staff

"[Sacral neuromodulation has] changed the treatment of OAB remarkably," says Howard B. Goldman, MD, FACS.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Howard Goldman, MD, discusses the development of sacral neuromodulation as a treatment for overactive bladder (OAB). Goldman is a professor of urology and vice chair of the Glickman Urologic Institute at Cleveland Clinic.

Related Videos
Colin Goudelocke, MD, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
William Furuyama, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury
March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke
The 52-week study plans to enroll 16 patients across 4 sites in the US.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Pivotal study data show efficacy of percutaneous SNM device for UUI
February 28th 2025

Pivotal study data show efficacy of percutaneous SNM device for UUI

Hannah Clarke
Overall, 84.2% of patients achieved a 50% or greater reduction in urgent leaks.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Published OASIS data show durable efficacy of Revi System for UUI
February 7th 2025

Published OASIS data show durable efficacy of Revi System for UUI

Hannah Clarke
At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.
ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures
January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke
Functional success was achieved in 58% of patients at 5-year follow-up.
© 2025 MJH Life Sciences

All rights reserved.